18 and older, any sex, with Advanced Solid Tumor or Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Phase 1: Number or Participants With Dose Limiting Toxicities (DLTs)Primary· Cycle 1 (21 Day Cycle)
DLT is defined as an event that is clinically significant and not clearly related to disease progression or intercurrent illness that occurred within the DLT observation period of the Cycle 1 timeframe.
Group
Value
95% CI
LY3499446 Phase 1 Cohort A1 (High Dose)
2
LY3499446 Phase 1 Cohort AO (Mid Dose)
1
LY3499446 Phase 1 Cohort A-2 (Low Dose)
1
Phase 1: Pharmacokinetics (PK): Average Concentration of LY3499446Secondary· Cycle 1 Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 8, 24 hours post-dose
Average concentration after the first dose of LY3499446.
Group
Value
95% CI
LY3499446 Phase 1 Cohort A1 (High Dose)
NA
± NA
LY3499446 Phase 1 Cohort AO (Mid Dose)
NA
± NA
LY3499446 Phase 1 Cohort A-2 (Low Dose)
NA
± NA
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline up to 11 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07300943 — Study in Advanced Solid Tumor Patients
· Phase 1, PHASE2
· recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors
· Phase 1
· recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity
· Phase 1, PHASE2
· recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
· Phase 1
· recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli
· Phase 1
· recruiting
Other Eli Lilly and Company trials
Trials by the same sponsor.
NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
· Phase 2
· not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
· Phase 2
· not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants
· Phase 1
· completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
· Phase 1
· completed
NCT07030127 — A Study of LY3985863 in Healthy Participants
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 24 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04165031.